Hyperbaric Oxygen Therapy for Peripheral Artery Disease (PAD)

Important: Hyperbaric oxygen therapy is not FDA-approved for chronic peripheral artery disease or intermittent claudication, and it is not a UHMS-listed indication. This is an investigational use. The evidence is preliminary and limited. Insurance will not cover HBOT for this condition. All costs are out-of-pocket.

Peripheral artery disease narrows the arteries that carry blood to the legs, usually from the same plaque buildup that affects the heart. The classic symptom is intermittent claudication: a cramping ache in the calf or thigh that comes on with walking and eases with rest. People living with that ache search for anything that might restore blood flow, and hyperbaric oxygen therapy comes up because it raises the oxygen content of blood. The honest position is that HBOT is not an established treatment for the arterial disease itself, it is not FDA-approved for it, and no insurer covers it for this use.

There is an important point of confusion to clear up first, because it changes everything about coverage.

Two Different Conditions That Sound Alike

Medicare’s National Coverage Determination 20.29 lists “acute peripheral arterial insufficiency” among its covered HBOT indications. That phrase looks like it should cover PAD, but it does not describe chronic PAD or claudication. Acute peripheral arterial insufficiency means a sudden arterial occlusion that cuts off blood to a limb, an emergency where surgical or interventional options are limited. Chronic PAD is the slow narrowing that produces claudication over months and years. They share words. They are not the same diagnosis, and only the acute form appears on the covered list.

So when a clinic says HBOT is “on the Medicare list for peripheral arterial” problems, that is technically true for the acute emergency indication and false for chronic claudication. If you have stable PAD with leg pain on walking, the covered acute indication does not apply to you.

Where HBOT Does Have a Role Near PAD

The place HBOT has real, covered use is the wound, not the artery. PAD can lead to skin breakdown and ulcers on the lower legs and feet because the tissue is starved of blood. When one of those wounds fails to heal after standard care, it may meet criteria for HBOT as an adjunct to wound treatment. That coverage attaches to the qualifying wound and its documentation, not to the PAD diagnosis on its own.

If a wound is part of your situation, these pages cover the territory directly:

• Non-healing wounds explains which chronic wounds qualify and how candidacy is assessed.
• Diabetic wounds covers the lower-extremity diabetic ulcers that have the most detailed coverage criteria.
• Diabetic neuropathy addresses nerve damage, which often travels alongside vascular disease but is a distinct problem.
• Avascular necrosis covers bone death from interrupted blood supply, another circulation-related use that is sometimes confused with PAD.

None of those pages are about treating PAD or claudication itself. They are about specific wound, nerve, and bone problems that can arise when circulation is poor.

What the Evidence Actually Shows

For HBOT and the arterial disease itself, there is a rationale and not much published trial data. The reasoning goes like this: HBOT dissolves extra oxygen into blood plasma at increased pressure, and in wound-healing settings it appears to support angiogenesis, the growth of new blood vessels. The idea is that repeated sessions might encourage new vessel growth in poorly perfused legs. That is a hypothesis drawn from wound biology, not a demonstrated effect on claudication, and a mechanism that helps a chronic wound does not automatically improve walking distance in PAD.

The stronger evidence in this neighborhood is about wounds, and it is mixed. The 2015 Cochrane systematic review by Kranke et al. pooled randomized trials of HBOT for chronic wounds. It found that HBOT improved diabetic foot ulcer healing in the short term, around six weeks, but that the advantage did not hold at one year. For major amputation, the review reported no statistically significant difference between treated and control groups. The authors also flagged that the underlying trials had flaws in design and reporting, which limits how much weight the results can carry (PMID: 26106870). That is a careful, qualified finding about wound healing. It is not evidence that HBOT treats peripheral artery disease, restores blood flow to a claudicating leg, or relieves claudication symptoms.

So the summary is narrow. Direct trial evidence for HBOT in chronic claudication is limited. The better-studied use nearby is wound healing, and even there the benefit is short-term and the amputation data did not reach significance. Anyone presenting HBOT as a proven circulation fix for PAD is going past what the published research supports.

What Standard PAD Care Looks Like

For context, chronic PAD has treatments with far stronger evidence behind them. First-line management centers on cardiovascular risk reduction: stopping smoking, controlling blood pressure, treating high cholesterol, and managing diabetes. Supervised exercise therapy, specifically structured walking programs, has solid trial support for improving walking distance in claudication. Medications and, for more advanced disease, revascularization procedures such as angioplasty, stenting, or bypass surgery are options a vascular specialist weighs based on the individual case.

That is not medical advice for your situation. The point is that people considering HBOT for PAD are usually weighing it against treatments with decades of controlled-trial support, and that comparison belongs in the conversation with a vascular specialist rather than with a clinic selling hyperbaric packages.

Cost and the Marketing Around It

Because chronic PAD and claudication are not FDA-approved or UHMS-listed HBOT indications, no insurer will cover HBOT for them, and Medicare’s acute peripheral arterial insufficiency listing does not apply. The cost falls entirely on the patient. HBOT sessions typically run $250 to $450 each, and investigational protocols often involve 40 or more sessions, which puts an out-of-pocket course in the rough range of $10,000 to $18,000 or higher. Rates change and vary by facility, so confirm any figure with the clinic’s billing team before committing.

Be skeptical of any clinic that blurs the line between the covered acute indication and chronic PAD, quotes wound-healing studies as if they were claudication studies, or implies that insurance “might” pay when it will not. The same caution that applies to any off-label HBOT use worth weighing carefully applies here. If a provider is making confident claims that HBOT improves circulation in PAD, the published evidence does not back that confidence.

Frequently Asked Questions

Is HBOT a proven treatment for peripheral artery disease? No. There is a biological rationale and limited direct trial evidence. The better-studied nearby use is chronic wound healing, and even that evidence is short-term and qualified. None of it establishes HBOT as a treatment for the arterial disease or for claudication.

My doctor mentioned PAD is on a Medicare HBOT list. Is mine covered? The covered item is acute peripheral arterial insufficiency, a sudden arterial occlusion causing limb ischemia. That is different from chronic PAD with claudication, which is not on the list. Ask your care team and the facility’s billing team to confirm which diagnosis applies to you.

I have PAD and a leg ulcer that won’t heal. Can HBOT be covered? Possibly, but the coverage would attach to the qualifying non-healing wound, not to the PAD itself. See the non-healing wounds page for how candidacy and documentation work, and have your wound care team evaluate your case against the criteria.

How much does HBOT cost out-of-pocket for PAD? Sessions typically run $250 to $450 each, and investigational protocols often use 40 or more sessions, so a course commonly lands around $10,000 to $18,000 or more. Rates change and vary by facility, so verify with the clinic.

References

Kranke, P. et al. (2015). Hyperbaric oxygen therapy for chronic wounds. Cochrane Database of Systematic Reviews. PMID: 26106870. https://pubmed.ncbi.nlm.nih.gov/26106870/

Centers for Medicare and Medicaid Services. National Coverage Determination (NCD) 20.29, Hyperbaric Oxygen Therapy. The covered list includes acute peripheral arterial insufficiency, not chronic peripheral artery disease or intermittent claudication. https://www.cms.gov/medicare-coverage-database/

The Undersea and Hyperbaric Medical Society (UHMS), Hyperbaric Oxygen Therapy Indications (14th ed.), lists the accepted indications for HBOT. Chronic peripheral artery disease and intermittent claudication are not among them. https://www.uhms.org/

U.S. Food and Drug Administration. Hyperbaric Oxygen Therapy: Get the Facts. HBOT is cleared for a defined set of indications, and chronic PAD is not one of them. https://www.fda.gov/consumers/consumer-updates/hyperbaric-oxygen-therapy-get-facts

Browse all conditions on the conditions hub. For more on weighing investigational uses, see off-label HBOT and what to consider. To find an accredited provider, visit the provider directory.

Medical Disclaimer: This page is for informational purposes only. It does not constitute medical advice, diagnosis, or treatment. Hyperbaric oxygen therapy for chronic peripheral artery disease is investigational and not FDA-approved. Always consult a qualified healthcare provider before pursuing any medical treatment.